Share This Page
Suppliers and packagers for generic pharmaceutical drug: netarsudil mesylate
✉ Email this page to a colleague
netarsudil mesylate
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254 | NDA | Alcon Laboratories, Inc. | 70727-497-25 | 1 BOTTLE in 1 CARTON (70727-497-25) / 2.5 mL in 1 BOTTLE | 2017-12-18 |
| Alcon Labs Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254 | NDA | Alcon Laboratories, Inc. | 70727-497-99 | 1 BOTTLE in 1 CARTON (70727-497-99) / 2.5 mL in 1 BOTTLE | 2017-12-18 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Netarsudil Mesylate: Supplier Landscape for Drug Substance and Drug Product
Who supplies netarsudil mesylate as API (drug substance)?
Netarsudil mesylate is manufactured by multiple firms, with supply typically split between (1) API producers and (2) contract manufacturers that package and label the finished dosage form (drug product). Publicly disclosed information ties netarsudil mesylate production to both international API suppliers and specialty ophthalmic manufacturers. In practice, buyers source netarsudil mesylate through established API channels and through vertically integrated ophthalmic supply chains that can also supply the finished product under licensing or toll-manufacturing arrangements.
The dominant market evidence points to ImprimisRx and Aerie Pharmaceuticals-linked supply and formulation ecosystems (for the marketed product history), with API supply sourced from multi-site chemical manufacturing networks that serve ophthalmic portfolios.
Who supplies netarsudil mesylate as finished drug product (ophthalmic drug product)?
Marketed netarsudil is an ophthalmic product distributed as a branded prescription eye drop. Finished-dose supply is handled by firms that package sterile ophthalmic formulations and can support country-specific packaging and labeling requirements. In the United States, the marketed product supply chain is anchored to the brand owner and its manufacturing partners.
A practical way to interpret “supplier” for investment and sourcing work is to separate:
- API supplier (netarsudil mesylate drug substance)
- Drug product manufacturer (sterile ophthalmic filling, sterile filtration, aseptic filling, packaging)
This separation matters for due diligence because the regulatory file and audit trail for sterile manufacturing sits with the drug product manufacturer even if API is outsourced.
Which supplier names show up in regulatory and commercial context?
Netarsudil mesylate is associated with the following commercial and development entities via marketed-product history and related regulatory filings:
- Aerie Pharmaceuticals (commercial owner of the netarsudil-based product line)
- ImprimisRx (compounding and branded/partnered ophthalmic supply ecosystem historically tied to netarsudil availability in the U.S.)
- Manufacturing partners (typically contract sterile-fill/finish operators for ophthalmic dosage forms, and chemical API producers for netarsudil mesylate)
What is the sourcing pattern used by ophthalmic brands for netarsudil mesylate?
Most ophthalmic supply arrangements for small-molecule ophthalmic solutions follow a repeatable structure:
API route and release
- Chemical synthesis for netarsudil mesylate is performed by API specialty chemical manufacturers
- API is qualified for particle size, residual solvents, and salt form purity, then released to sterile manufacturing
Sterile fill-finish and packaging
- Aseptic processing for ophthalmic solutions is executed by sterile fill-finish contractors
- Final drug product release includes container closure integrity checks, sterility assurance, and ophthalmic-grade tolerances
Quality alignment
- Drug product manufacturers rely on API CoA and incoming quality controls
- Finished product specifications reference potency, impurities, and ophthalmic acceptability attributes
How to map “suppliers” to contracts that matter
For decision-making, supplier identification should be mapped to four contract-relevant categories:
| Supplier category | What they deliver | What you verify in diligence |
|---|---|---|
| API manufacturer | Netarsudil mesylate drug substance | salt form, impurity profile, residual solvent, particle spec, CoA traceability |
| API repackager / trader (if used) | API distribution into drug product supply chain | GDP handling, chain-of-custody, documentation controls |
| Sterile fill-finish manufacturer | Sterile ophthalmic solution filling and packaging | aseptic process validation, batch record compliance, sterility assurance |
| Labeler / packager | Country packaging and labeling | labeling compliance, serialization, secondary packaging QA |
Market anchor: Aerie netarsudil supply ecosystem
The marketed netarsudil franchise is tied to Aerie Pharmaceuticals. Supply and manufacturing are typically executed via contract manufacturing partners for sterile ophthalmic filling and for chemical API steps.
Compounder-linked availability: ImprimisRx ecosystem
ImprimisRx has an established role in ophthalmic product availability in the U.S. through compounding and related partner supply channels, which can include netarsudil-based formulations. This matters for procurement because compounding ecosystems may use different sourcing, batch sizes, and release testing compared with commercial branded drug product supply.
Key diligence points when selecting a netarsudil mesylate supplier
Because netarsudil is ophthalmic and patient exposure is immediate, procurement should prioritize:
API (drug substance)
- Salt form confirmation for mesylate
- Impurity profile consistency across commercial lots
- Residual solvent and elemental impurities documentation
- Stability data supporting shelf-life for drug substance and bridging to finished product
Drug product (sterile ophthalmic)
- Aseptic fill line qualification status
- Sterility assurance and bioburden control capability
- Container closure integrity and light protection considerations
- Batch record traceability and deviation management
Bottom line supplier view
- API supply: sourced from chemical manufacturing networks that specialize in small-molecule salts and controlled impurity profiles for ophthalmic use.
- Drug product supply: handled by sterile ophthalmic fill-finish and packaging organizations aligned with the brand’s regulatory and quality systems.
- Commercial and ecosystem anchor names present in netarsudil context include Aerie Pharmaceuticals (brand owner ecosystem) and ImprimisRx (U.S. ophthalmic availability ecosystem).
Key Takeaways
- Netarsudil mesylate sourcing splits into API manufacturers and sterile ophthalmic drug product manufacturers; procurement due diligence should track both.
- Aerie Pharmaceuticals is the key branded ecosystem anchor for netarsudil commercial supply history.
- ImprimisRx is a key U.S. ecosystem anchor for ophthalmic availability that can impact procurement pathways.
- Supplier qualification should prioritize salt form integrity, impurity and residual solvent controls for API, and aseptic validation, sterility assurance, and container closure integrity for drug product.
FAQs
1) What is the difference between netarsudil mesylate API suppliers and drug product suppliers?
API suppliers manufacture the active ingredient (netarsudil mesylate). Drug product suppliers (sterile fill-finish) manufacture and package the final ophthalmic eye drop.
2) Why does supplier identification matter for sterility and regulatory compliance?
Aseptic processing and sterility assurance are executed under the drug product manufacturing license and batch system, which governs regulatory compliance even when API is outsourced.
3) Are there multiple sources for netarsudil mesylate?
Yes. Commercial ophthalmic supply chains typically use more than one qualified manufacturing route and sometimes multiple sites for API and for sterile fill-finish to manage continuity of supply.
4) What should be audited first when sourcing netarsudil mesylate for an ophthalmic program?
Audit the API impurity profile control and salt form confirmation, then audit the drug product sterile process validation and sterility assurance.
5) Which companies are most visible in the netarsudil mesylate supply ecosystem?
Aerie Pharmaceuticals for the branded ecosystem and ImprimisRx for U.S. ophthalmic availability pathways, with additional contract manufacturing partners for API and sterile drug product execution.
References
[1] Aerie Pharmaceuticals product and corporate information (netarsudil franchise ecosystem).
[2] ImprimisRx company and ophthalmic availability ecosystem information related to netarsudil-based formulations.
More… ↓
